AJOG: CD70 Antibody-Drug Coupler is expected to be a target drug for uterine smooth muscoma.

Uterine smooth muscle tumor is a rare aggressive gynaecological malignancies that originate in the uterine muscle layer and remain at high risk of recurrence after complete surgical removal.
current drug has only a moderate effect on uterine smooth muscle tumors.
antibody and antibody-drug concourse (ADC) have been recognized as effective target therapies for other cancers, but no studies have been conducted to assess the effects of this method on uterine smooth muscle tumors.
study aims to study the activity of CD70 tumor clusters in uterine smooth muscle tumors and to evaluate the anti-tumor activity of CD70-ADC in treating uterine smooth muscle tumors.
researchers first screened target membrane proteins by comparing the expression of membrane proteins in three uterine smooth muscular tumor cell lines (SK-UT-1, SK-LMS-1 and SKN) and normal uterine myoblasts.
then used a variety of methods to detect the level of expression of membrane protein CD70 in uterine smooth muscoma cell lines and clinical samples.
developed a monoclonal antibody of the target membrane protein in association with the ADC of monomedehylastatin F (MMAF) and studied its anti-tumor effect on uterine smooth muscle tumors.
, CD70 is a highly expressed specific antigen in the uterine smooth muscular tumor cell line.
cd70 expression in SK-LMS-1 cells was confirmed by Western imprinting and fluorescence-activated cell sub-analysis in three uterine smooth muscle tumor cell lines.
CD70 over-expression was observed in 90.5% (19/21) of clinical samples.
(CD70-ADC treatment on tumor volume in transplanted mouse models) researchers coupled anti-CD70 monoclonal antibodies with new derivatives of MMAF to produce CD70-ADC.
CD70-ADC has significant anti-tumor effects on SK-LMS-1 cells (IC50 is 0.120 nM), but no anti-tumor effect on CD70-negative uterine smooth muscle tumor cell lines.
in the SK-LMS-1 heterogeneity transplant mouse model and the patient-source tumor transplant model, CD70-ADC significantly inhibited tumor growth (tumor volume: 129.8 vs 285.5 mm3, 128.1 vs 837.7 mm3).
high expression CD70 of uterine smooth muscoma, with CD70-ADC targeted treatment of uterine smooth muscle tumors or can obtain good therapeutic results.
.